Skip to content
Search

Latest Stories

Infosys posts highest revenues in decade on strong demand

Indian software giant Infosys reported a 22.7-percent increase in quarterly net profit on Wednesday (14) after its revenues soared to their highest in a decade as global demand for digital services boomed during the pandemic.

The company increased its full-year revenue guidance by two percent to 14 to 16 per cent on the back of expectations of strong demand, particularly for its digital services.


The country's software services industry has been a bright spot in the economy, which has been badly hit by the virus and lockdowns, rebounding in recent months as companies like Infosys secured new orders.

Net profit at India's second-largest IT company rose to 51.95 billion rupees ($698 million) in the quarter ending June 30 compared to 42 billion rupees a year ago, just below analysts' expectations.

Quarterly revenues jumped by 17.9 per cent to 278.96 billion rupees, from 236 billion rupees for the same period last year.

"We've had a landmark first quarter," the Bangalore-headquartered firm's chief executive Salil Parekh told reporters.

"This is the fastest growth we've seen in ten years."

The company signed deals worth $2.6 billion in the quarter, up from $2.1 billion in the previous quarter.

Revenues from digital services rose by 42 per cent year-on-year.

But the company's core consulting and technology business contracted by three percent for the same period.

Infosys was at the forefront of an outsourcing boom that saw the country become a back office to the world, as Western firms subcontracted work to a skilled English-speaking workforce.

Over 60 percent of its revenue comes from North American markets.

Shares in the company closed just over two percent higher on Wednesday ahead of the earnings announcement.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less